Subsequent Cancers in Patients Potentially Cured of AML
| Patient No. . | Subsequent Cancer . | Age at Diagnosis Subsequent Cancer . | Sex . | Years From Entry Into Potentially Cured Cohort to First Diagnosis of Subsequent Cancer* . | Cytogenetics at Leukemia Diagnosis . | Leukemia Treatment Initial/Salvage . |
|---|---|---|---|---|---|---|
| 1 | Colon-adenocarcinoma | 68 | M | 2 | Normal | ROAP |
| 2 | Colon-adenocarcinoma | 77 | M | 9 | Complex-7 | ADOAP/ADOAP |
| 3 | Lung-carcinoid/colon/breast | 69 | F | 14 | Normal (unbanded) | ADOAP |
| 4 | Lung-small cell carcinoma | 62 | F | 18 | Insufficient | ADOAP |
| 5 | Lung-adenocarcinoma | 65 | F | 1 | Normal (unbanded) | ROAP |
| 6 | Pancreas/melanoma | 68 | M | 4 | Normal | AMSA + OAP |
| 7 | Prostate | 60 | M | 2 | Inv 16 | IDA + HDAC |
| 8 | Prostate | 73 | M | 4 | t(8; 21) | AMSA + OAP |
| 9 | Breast | 51 | F | 2 | Inv 16 | AMSA + OAP |
| 10 | Endometrial | 82 | F | 17 | Insufficient | ADOAP |
| 11 | Endometrial | 58 | F | 11 | t(8; 21) (unbanded) | ADOAP/ADOAP |
| 12 | Penile-squamous | 49 | M | 14 | 47XY + G (unbanded) | ARA-C |
| 13 | Lymphoma-NHL | 48 | M | 13 | Normal | ADOAP |
| 14 | Lymphoma-DLCL | 63 | M | 3 | Inversion 5, +8, +4 | HDAC/FLUDARABINE + ARA-C |
| 15 | Bladder-TCC | 58 | M | 5 | +8 (unbanded) | ADOAP |
| Patient No. . | Subsequent Cancer . | Age at Diagnosis Subsequent Cancer . | Sex . | Years From Entry Into Potentially Cured Cohort to First Diagnosis of Subsequent Cancer* . | Cytogenetics at Leukemia Diagnosis . | Leukemia Treatment Initial/Salvage . |
|---|---|---|---|---|---|---|
| 1 | Colon-adenocarcinoma | 68 | M | 2 | Normal | ROAP |
| 2 | Colon-adenocarcinoma | 77 | M | 9 | Complex-7 | ADOAP/ADOAP |
| 3 | Lung-carcinoid/colon/breast | 69 | F | 14 | Normal (unbanded) | ADOAP |
| 4 | Lung-small cell carcinoma | 62 | F | 18 | Insufficient | ADOAP |
| 5 | Lung-adenocarcinoma | 65 | F | 1 | Normal (unbanded) | ROAP |
| 6 | Pancreas/melanoma | 68 | M | 4 | Normal | AMSA + OAP |
| 7 | Prostate | 60 | M | 2 | Inv 16 | IDA + HDAC |
| 8 | Prostate | 73 | M | 4 | t(8; 21) | AMSA + OAP |
| 9 | Breast | 51 | F | 2 | Inv 16 | AMSA + OAP |
| 10 | Endometrial | 82 | F | 17 | Insufficient | ADOAP |
| 11 | Endometrial | 58 | F | 11 | t(8; 21) (unbanded) | ADOAP/ADOAP |
| 12 | Penile-squamous | 49 | M | 14 | 47XY + G (unbanded) | ARA-C |
| 13 | Lymphoma-NHL | 48 | M | 13 | Normal | ADOAP |
| 14 | Lymphoma-DLCL | 63 | M | 3 | Inversion 5, +8, +4 | HDAC/FLUDARABINE + ARA-C |
| 15 | Bladder-TCC | 58 | M | 5 | +8 (unbanded) | ADOAP |
Abbreviations: NHL, non-Hodgkin's lymphoma; DLCL, diffuse large-cell lymphoma; TCC, transitional cell carcinoma; ADOAP, adriomycin, ara-C, vincristine, prednisone; ROAP, rubidazone, ara-C, vincristine, prednisone; HDAC, high-dose ara-C.
Add 3 years to determine time from initial AML therapy to subsequent cancer.